Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ascendis Pharma ( (ASND) ) just unveiled an update.
Ascendis Pharma announced that the FDA has accepted their supplemental Biologics License Application for TransCon hGH in treating adult growth hormone deficiency. The decision marks a significant step in expanding the use of their already approved pediatric treatment, SKYTROFA, to adults, potentially enhancing their market position and offering new treatment options for adult patients.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focusing on developing innovative therapies in endocrinology, oncology, and other therapeutic areas. Their primary products and services target complex medical conditions, with an emphasis on creating long-acting prodrug therapies using their proprietary TransCon technology.
YTD Price Performance: 6.61%
Average Trading Volume: 555,279
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $8.02B
For detailed information about ASND stock, go to TipRanks’ Stock Analysis page.
